HIF-1α促进卵巢癌贝伐单抗耐药的研究

doi:10.11904/j.issn.1002-3070.2015.04.002

Abstract

Abstract: Objective To investigate the relationship between HIF-1α and bevacizumab resistant in ovary cancer,and explore the influence on ovary cancer cell by HIF-1α.Methods The correlation was analyzed between HIF-1α expression and clinicopathological parameters using immunohistochemistry in 62 patients with ovarian cancer.In addition,the expression of HIF-1α and VEGF were evaluated by real time PCR or Western Blot in SKOV3 and ES-2 cell under CoCl 2 treatment.Results HIF-1α was overexpressed in cancer tissue,and its high levels were related to CA125(P=0.027)and resistant to bevacizumab(P＜0.001).Moreover,CoCl2 could induce high expressions of HIF-1α and VEGF,when compared to normal condition.Conclusion Our findings suggest that HIF-1α is associated with resistant to bevacizumab.It is more chemotherapeutic sensitivity when combined with bevacizumab and HIF-1α antibody.

Key words: Bevacizumab, HIF-1α, Ovarian cancer

CLC Number:

R734.2

YU Ge,YANG Xian,LIU Xiaodong,SHAO Hua,ZHAO Yulan,WANG Jing. HIF-1α induces ovarian cancer to resistant to bevacizumab[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 294-298.

References

1 Siegel R,Ma J,Zou Z,et al.Cancer statistics,2014[J].CA:A Cancer Journal for Clinicians,2014,64(1):9-29.
2 Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].New Engl J Med,2011,365(26):2473-2483.
3 Perren TJ,Swart AM,Pfisterer J,et al.A phase 3 trial of bevacizumab in ovarian cancer[J].New Engl J Med,2011,365(26):2484-2496.
4 Abu-Jawdeh GM,Faix JD,Niloff J,et al.Strong expression of vascular permeability factor(vascular endothelial growth factor)and its receptors in ovarian borderline and malignant neoplasms[J].Lab Invest,1996,74(6):1105-1115.
5 Burger RA,Sill MW,Monk BJ,et al.Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:a Gynecologic Oncology Group Study[J].J Clin Oncol,2007,25(33):5165-5171.
6 Penson RT,Dizon DS,Cannistra SA,et al.Phase II study of carboplatin,paclitaxel,and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mülleriantumors[J].J Clin Oncol,2010,28(1):154-159.
7 Cannistra SA,Matulonis UA,Penson RT,et al.Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer[J].J Clin Oncol,2007,25(33):5180-5186.
8 Garcia AA,Hirte H,Fleming G,et al.Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer:a trial of the California,Chicago,and Princess Margaret Hospital phase II consortia[J].J Clin Oncol,2008,26(1):76-82.
9 Chura JC,Van Iseghem K,Downs LS,et al.Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer[J].Gynecol Oncol,2007,107(2):326-330.
10 Christofk HR,Vander Heiden MG,Harris MH,et al.The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J].Nature,2008,452(7184):230-233.
11 Liang Y,Zheng T,Song R,et al.Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma[J].Hepatology,2013,57(5):1847-1857.
12 程林峰,杨向民.缺氧诱导因子-1 与肿瘤的关系[J].实用肿瘤学杂志,2007,21(4):370-373.
13 Ahn GO,Seita J,Hong BJ,et al.Transcriptional activation of hypoxia-inducible factor-1(HIF-1)in myeloid cells promotes angiogenesis through VEGF and S100A8[J].P Natl Acad Sci USA,2014,111(7):2698-2703.
14 Wong C,Wellman TL,Lounsbury KM.VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer[J].Gynecol Oncol,2003,91(3):513-517.
15 Cao D,Hou M,Guan YS,et al.Expression of HIF-1alpha and VEGF in colorectal cancer:association with clinical outcomes and prognostic implications[J].BMC Cancer,2009,9(1):432-441.
16 Kim SJ,Rabbani ZN,Dewhirst MW,et al.Expression of HIF-1α,CA IX,VEGF,and MMP-9 in surgically resected non-small cell lung cancer[J].Lung Cancer,2005,49(3):325-335.
17 Zhu P,Ning Y,Yao L,et al.The proliferation,apoptosis,invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia[J].J Exp Clin Cancer Res,2010,29(10):124-132.
18 Huang L,Ao Q,Zhang Q,et al.Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1α[J].J Cancer Res Clin,2010,136(3):447-456.
19 Lucio-Eterovic AK,Piao Y,de Groot JF.Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy[J].Clin Cancer Res,2009,15(14):4589-4599.
20 Miyoshi A,Kitajima Y,Ide T,et al.Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1α-independent manner[J].Int J Oncol,2006,29(6):1533-1539.
21 Song G,Ouyang G,Mao Y,et al.Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1α up-regulation and MMP9 activation[J].J Cell Mol Med,2009,13(8b):1706-1718.
22 Liu T,Zhao L,Chen W,et al.Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway[J].Int J Mol Med,2014,33(5):1236-1242.

[1]	LV Bowen, QIAN Jun, WANG Jie, QIAN Jingrong, LU Yingying, SU Liju, YANG Tongshu, LI Wenhui. Expression of MiR-455-5p in epithelial ovarian cancer and its target gene function [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 115-121.
[2]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[3]	SONG Ling, FU Qiong. Study of the effect of astragalin on proliferation of ovarian cancer cells by inhibiting the glycolytic pathway induced Via HIF-1α [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 503-509.
[4]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[5]	LIANG Guanying,CHI Qiujun,LI Xiaomei. Effect and mechanism of Vorinostat on the proliferation and apoptosis of ovarian cancer SKOV3 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 298-302.
[6]	LI Wenhui, LV Bowen, QIAN Jun, SU Liju, YANG Tongshu, QIAN Jingrong, WANG Jie. Effect of microRNA-150 on proliferation,apoptosis,invasion and metastasis of epithelial ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 208-213.
[7]	BI Qiling, ZHOU Lihong, HAN Yimin. Research progress of HOX gene and gynecologic tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 140-143.
[8]	LIU Xin, XU Yingjuan, YANG Chang, LOU Ge. Research progress on cadherins and integrins in ovarian epithelial cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 548-553.
[9]	YU Ge,SUN Jianing,FENG Xiaoling. Expression of PSMD10 and Ki67 in epithelial ovarian carcinoma and its clinicopathological significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 112-116.
[10]	CHAI Jingbo, LI Ping, PEI Zhiping. The effects and mechanism of Lycopene on immune function of ovarian cancer rats [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 13-17.
[11]	YU Dongyang,LIU Ziliang,HAN Lirong. The clinical features,curative effect and prognosis factors analysis in 58 patients with advanced ovarian cancer after intraperitoneal metastases [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 321-326.
[12]	DENG Yanhong ,LE Xiu ,GAO Wenchao. The effects of anti-cancer drug NSC319726 on the gene expression of ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 332-338.
[13]	GUO Shuang, LIU Duanyang, LI Jing, LI Jiade, JIN Xiaoming. The effect of malignant ascites on the proliferation and migration of ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 36-40.
[14]	CHEN Jie,HOU Encun. Advances in bevacizumab combined with XELOX regimen in the treament of metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 157-161.
[15]	JIN Hong,XIE Kai,ZHANG Meili,SUN Jing,DONG Youyuan. Effect of cIAP1 down-regulation mediated by shRNA on biological behavior of human ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 17-21.

HIF-1α induces ovarian cancer to resistant to bevacizumab

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments